13 Biotechnology Stocks to Sell Now

13 Biotechnology Stocks to Sell Now

The overall ratings of 13 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Kite Pharma, Inc. (KITE) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of KITE stock.

This is a rough week for Grifols, S.A. Sponsored ADR Class B (GRFS). The company’s rating falls to D from the previous week’s C. Grifols, S.A. Sponsored ADR Class B develops, manufactures, and markets plasma derivatives, IV Therapy, Enteral nutrition, diagnostic systems, and medical materials. For more information, get Portfolio Grader’s complete analysis of GRFS stock.

Applied Genetic Technologies Corp. (AGTC) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of AGTC stock.

Trevena, Inc. (TRVN) declines this week from a D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

ZIOPHARM Oncology, Inc. (ZIOP) experiences a ratings drop this week, going from last week’s D to a F. ZIOPHARM Oncology, Inc. is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

Medgenics, Inc.’s (MDGN) rating weakens this week, dropping to a F versus last week’s D. Medgenics, Inc. is a biopharmaceutical company that develops therapeutic protein delivery technology for the treatment of a range of chronic diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MDGN stock.

Slipping from a C to a F rating, Vascular Biogenics Ltd. (VBLT) takes a hit this week. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VBLT stock.

Spectrum Pharmaceuticals, Inc. (SPPI) slips from a D to a F this week. Spectrum Pharmaceuticals, Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of SPPI stock.

Opexa Therapeutics, Inc. (OPXA) gets weaker ratings this week as last week’s C drops to a D. Opexa Therapeutics, Inc. develops cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, pancreatic, and cardiac conditions. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OPXA stock.

This week, Can-Fite BioPharma Ltd. Sponsored ADR’s (CANF) rating worsens to a D from the company’s B rating a week ago. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CANF stock.

This week, ArQule, Inc. (ARQL) drops from a C to a D rating. ArQule, Inc. is a biotechnology company that is engaged in the research and development of cancer therapeutics. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARQL stock.

Slipping from a C to a D rating, Macrocure Ltd. (MCUR) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MCUR stock.

Heat Biologics, Inc. (HTBX) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of HTBX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/10/13-biotechnology-stocks-to-sell-now-4/.

©2019 InvestorPlace Media, LLC